SIGN UPLog In

General

Financials

People

Founders
Employee Profiles

Activity

Recent News
Prosonix
Prosonix
Company

Last deal

$26.81M
Local Amount - GBP 17.1M

Amount

Series B

Stage

24.05.2012

Date

2

all rounds

$45.05M

Total amount

date founded

Financing round

General

About Company
Prosonix is a pharmaceutical company that specializes in developing inhaled respiratory medicines.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2006

founders

Number of employees

11-50

Company Type

For Profit

Last funding type

Series B

IPO status

Private

Description

The company is a leader in the commercialization of ultrasonic particle engineering technologies and process chemistry solutions. Using their ultrasonics particle-engineering platform, Prosonix can design and engineer drug particles that meet the specific requirements for inhalation, delivering the formula. Their core expertise lies in developing new methods for manufacturing inhaled medicines, from molecule to particle. Prosonix's portfolio includes mono- and combination drug particles, which are designed to treat a range of respiratory diseases.
Contacts

location

Oxford, UK

Phone number

Website URL

http://www.prosonix.co.uk
Similar Companies
1000
Flamel Technologies
Flamel TechnologiesFlamel Technologies SA is a specialty pharmaceutical company focused on developing safer and more effective drugs.
Flamel Technologies

Flamel Technologies

Flamel Technologies SA is a specialty pharmaceutical company focused on developing safer and more effective drugs.

Sector

Pharmaceuticals and Biotechnology

Subsector

Pharmaceuticals

Keywords

Pharmaceuticals, Biotechnology, Health Care

Location

69200 Vénissieux, France

total rounds

2

total raised

$31M
GL Pharmtech
GL PharmtechGL PharmTech develops improved pharmaceutical products with fewer side effects.
GL Pharmtech

GL Pharmtech

GL PharmTech develops improved pharmaceutical products with fewer side effects.

Sector

Pharmaceuticals and Biotechnology

Subsector

Pharmaceuticals

Keywords

Pharmaceuticals, Biotechnology, Health Care

Location

Seongnam-si, Gyeonggi-do, South Korea
Surface Pharmaceuticals
Surface PharmaceuticalsSurface Pharmaceuticals is a pharmaceutical company that develops ophthalmology products.
Surface Pharmaceuticals

Surface Pharmaceuticals

Surface Pharmaceuticals is a pharmaceutical company that develops ophthalmology products.

Sector

Pharmaceuticals and Biotechnology

Subsector

Pharmaceuticals

Location

California City, CA, USA

total rounds

3

total raised

$46.76M
OctoPlus
OctoPlusOctoPlus is a drug delivery company focused on developing improved pharmaceutical products with fewer side effects and better efficacy.
OctoPlus

OctoPlus

OctoPlus is a drug delivery company focused on developing improved pharmaceutical products with fewer side effects and better efficacy.

Sector

Pharmaceuticals and Biotechnology

Subsector

Pharmaceuticals

Location

Leiden, Netherlands

total rounds

2

total raised

$23.85M
M&A Details
1

Transaction name

Acquired by Circassia

Acquired by

Circassia
Circassia

Circassia

announced date

15.05.2015

price

$157.26M
Local Amount - GBP 100M

Financials

Funding Rounds
2
2

Number of Funding Rounds

$45.05M

Money Raised

Their latest funding was raised on 24.05.2012. Their latest investor Quest for Growth. Their latest round Series B

Date 
Funding Round 
Investors 
Money Raised 
Lead 
24.05.2012
Series B
6
$26.81M
Local Amount - GBP 17.1M
Gimv
Gimv
06.07.2011
Series B
5
$18.24M
Local Amount - GBP 11.4M
Ventech
Ventech
Gimv

Gimv

Gimv identifies and supports innovative companies with high-growth potential to become market leaders.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Venture Capital

Location

Antwerp, Belgium

count Of Investments

154

count Of Exists

49
Ventech

Ventech

Ventech is a European & Chinese early-stage investment fund that invests in the digital economy.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Financial Services, Finance

Location

Paris, France

count Of Investments

195

count Of Exists

41
Co-Investors
Investors
6
2

Number of lead investors

6

Number of investors

Investor 
Lead 
Round 
Partners 
Quest for Growth
Quest for Growth
No
Series B
—
Gimv
Gimv
Yes
Series B
Karl Nagler
Karl Nagler
Solon Ventures
Solon Ventures
No
Series B
—
Quest for Growth

Quest for Growth

Quest for Growth (QGPLF) is a Belgian Internet company that operates as a closed-end private equity fund.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Software, Financial Services

Location

Leuven, Belgium

count Of Investments

25

count Of Exists

10
Gimv

Gimv

Gimv identifies and supports innovative companies with high-growth potential to become market leaders.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Venture Capital

Location

Antwerp, Belgium

count Of Investments

154

count Of Exists

49
Karl Nagler

Karl Nagler

Karl Nagler is a Managing Partner at Wellington Partners Life Sciences. He attended the Free University of Berlin.

current job

Wellington Partners
Wellington Partners
Solon Ventures

Solon Ventures

Solon is a UK-based venture capital firm that invests in healthcare and technology sectors.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Financial Services, Health Care

Location

London, UK

count Of Investments

10

count Of Exists

6

People

Founders
1
David Hipkiss
David Hipkiss

David Hipkiss

current job

Circassia
Circassia

organization founded

1
David Hipkiss

David Hipkiss

Employee Profiles
5
David Hipkiss
David Hipkiss

David Hipkiss

Co-Founder & CEO

Co-Founder & CEO

Ken Cunningham

Ken Cunningham

Non-Executive Chairman

Non-Executive Chairman

Activity

Recent News
0